发布求助
文献互助 智能选刊 最新文献

Journal of Thoracic Oncology最新文献

筛选
英文 中文
An In-Depth Discussion on Dutch Prediction Models for Relevant Acute Toxicity and 90-Day Mortality After Stereotactic Body Radiotherapy for Stage I NSCLC 深入探讨立体定向体外放射治疗 I 期 NSCLC 后相关急性毒性和 90 天死亡率的荷兰预测模型
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.09.1427
{"title":"An In-Depth Discussion on Dutch Prediction Models for Relevant Acute Toxicity and 90-Day Mortality After Stereotactic Body Radiotherapy for Stage I NSCLC","authors":"","doi":"10.1016/j.jtho.2024.09.1427","DOIUrl":"10.1016/j.jtho.2024.09.1427","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to “Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813–819]” 对 "简要报告 "的勘误：加拿大癌症试验组 IND.227：pembrolizumab 用于晚期恶性胸膜间皮瘤患者的 II 期随机研究（NCT02784171）。[胸腔肿瘤学杂志》第 18 卷第 6 期：813-819]"。
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.017
{"title":"Erratum to “Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813–819]”","authors":"","doi":"10.1016/j.jtho.2024.08.017","DOIUrl":"10.1016/j.jtho.2024.08.017","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma IASLC 间皮瘤分期项目：关于即将出版的胸膜间皮瘤 TNM 分类第 9 版中 M 级描述符的建议。
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.022
{"title":"The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma","authors":"","doi":"10.1016/j.jtho.2024.08.022","DOIUrl":"10.1016/j.jtho.2024.08.022","url":null,"abstract":"<div><h3>Introduction</h3><div>The International Association for the Study of Lung Cancer developed a global multicenter database to propose evidence-based revisions for the ninth edition of the TNM classification of pleural mesothelioma (PM). This study analyzes the M category to validate eighth edition M category recommendations.</div></div><div><h3>Methods</h3><div>Cases were submitted electronically or by transfer of existing institutional databases for patients with histologically or cytologically confirmed PM. The presence and number of metastases (single versus multiple) in each of eight organ systems were reported for patients with M1 disease at diagnosis. Overall survival (OS) was calculated by the Kaplan-Meier method. Differences in OS were assessed by log-rank test.</div></div><div><h3>Results</h3><div>Of 7338 submitted cases, 3598 were eligible and 3221 had sufficient data for clinical staging; 228 cases (7%) were M1. Median overall estimated survival was inferior for M1 compared with M0 patients: 10.5 months versus 21.5 months, respectively (<em>p</em> &lt; 0.0001); estimated 1-year survival was 46% versus 71%, respectively. OS differences between M categories were preserved within histologic subgroups. Among 158 patients with organ-specific documentation of M1 disease, there was no statistically significant difference in OS between those with intrathoracic versus more distant metastatic disease (14.4 mo versus 10.9 mo, <em>p</em> = 0.64). No significant survival difference was detected between patients with metastatic disease in a single-organ system versus multiple-organ systems (12.6 mo versus 8.8 mo, <em>p</em> = 0.45).</div></div><div><h3>Conclusions</h3><div>This evidence-based analysis of the M category for PM conforms with the eighth edition M descriptors. No changes are proposed in the ninth edition of the mesothelioma M category.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on “Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to ‘False’ Decreases in Renal Function” 关于 "简要报告：抑制MATE-1的肺癌酪氨酸激酶抑制剂可导致肾功能 "错误 "下降"
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.07.020
{"title":"Comment on “Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to ‘False’ Decreases in Renal Function”","authors":"","doi":"10.1016/j.jtho.2024.07.020","DOIUrl":"10.1016/j.jtho.2024.07.020","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How Can We Conquer Lung Cancer? 如何战胜肺癌？
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.09.1377
{"title":"How Can We Conquer Lung Cancer?","authors":"","doi":"10.1016/j.jtho.2024.09.1377","DOIUrl":"10.1016/j.jtho.2024.09.1377","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung Cancer in Romania 罗马尼亚的肺癌
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.003
{"title":"Lung Cancer in Romania","authors":"","doi":"10.1016/j.jtho.2024.08.003","DOIUrl":"10.1016/j.jtho.2024.08.003","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tobacco News Update — From the IASLC Tobacco Control Committee 最新烟草新闻--来自 IASLC 烟草控制委员会的消息
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.09.1430
{"title":"Tobacco News Update — From the IASLC Tobacco Control Committee","authors":"","doi":"10.1016/j.jtho.2024.09.1430","DOIUrl":"10.1016/j.jtho.2024.09.1430","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to Comment on “Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to ‘False’ Decreases in Renal Function” 回复关于 "简要报告：抑制MATE-1的肺癌酪氨酸激酶抑制剂可导致肾功能 "假性 "下降"
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.026
{"title":"Reply to Comment on “Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to ‘False’ Decreases in Renal Function”","authors":"","doi":"10.1016/j.jtho.2024.08.026","DOIUrl":"10.1016/j.jtho.2024.08.026","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author’s Response to: Comment on “Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM Database” and “Critical Evaluation of Methodological Approaches in ALK TKI Research: Addressing Confounding Factors and Statistical Robustness” 作者的回应：关于 "EML4-ALK 变异和共存 TP53 突变对 ALK 融合阳性 NSCLC 一线 ALK 酪氨酸激酶抑制剂治疗持续时间和总生存期的影响：来自 GuardantINFORM 数据库的真实世界结果 "和 "ALK TKI 研究方法的批判性评估：解决混杂因素和统计稳健性问题"。
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.025
{"title":"Author’s Response to: Comment on “Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM Database” and “Critical Evaluation of Methodological Approaches in ALK TKI Research: Addressing Confounding Factors and Statistical Robustness”","authors":"","doi":"10.1016/j.jtho.2024.08.025","DOIUrl":"10.1016/j.jtho.2024.08.025","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to “Treatment response biomarkers: working towards personalised radiotherapy for lung cancer. [Journal of Thoracic Oncology Vol. 19 No. 8: 1164–1185]” 治疗反应生物标志物：努力实现肺癌的个性化放疗。[胸腔肿瘤学杂志》第 19 卷第 8 期：1164-1185]"的勘误。
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.021
{"title":"Erratum to “Treatment response biomarkers: working towards personalised radiotherapy for lung cancer. [Journal of Thoracic Oncology Vol. 19 No. 8: 1164–1185]”","authors":"","doi":"10.1016/j.jtho.2024.08.021","DOIUrl":"10.1016/j.jtho.2024.08.021","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信